Research
Hormonal
Obesity is a significant modifiable risk factor for atrial fibrillation (AF).
Practitioners should focus on managing obesity to reduce the risk of AF.
StrongSupportsmedium confidence
This comprehensive review underscores the critical role of obesity as a significant modifiable risk factor for AF.
Why this rating
The review synthesizes existing literature on the topic.
Source
Exploring the Intricate Interplay Between Obesity and Atrial Fibrillation: Mechanisms, Management, and Clinical Implications
Swati Chand et al. · Cardiology in Review · 2024
DOI 10.1097/crd.0000000000000651
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →